One step at a time.
Source: Psyche Wizzard
Homebuyer conditions for US consumers plummeted to their lowest level in history this month.
The index of buying conditions for houses fell to ~30 points which is below the previous low of ~40 points in the early 1980s. In just 4 years, conditions for buying a house have dropped by 110 points, a massive 73% decline. Meanwhile, buying conditions for vehicles and large household durables are down for 3 straight months. Source: The Kobeissi Letter
S&P 500 $SPX hasn't declined by 2% or more for 317 consecutive trading days, the longest streak since a 351-day stretch that lasted from Sep 2016 through Feb 2018.
Source: Barchart
The breadth in commodity price spikes is the highest in two years
Source: Bloomberg
The higher a stock's price goes, the more expensive it gets. Right? Well, not always.
A year ago, when NVDA was selling at $277, its earnings per share was $0.82 and its P/E ratio was 147x Today, NVDA's share price is up +284% to $1,064.... BUT... Its earnings per share is up +629% to $5.98. Its P/E has fallen to 62x... forward P/E is now at 30x So, NVDA is CHEAPER today than it was a year ago. Source: Adam Khoo Trader, Piranha Profits
Did you know that the S&P 500 has been basically flat vs gold over the last six years? 🤔
Source: Markets & Mayhem, BofA
A key point on Nvidia story: $NVDA CEO Jensen Huang doesn't lack demand. What he lacks is supply.
In an exclusive interview following last week's earnings Huang said demand for its programs will soon outstrip supply, with the complexity of these chips also challenging the company's efforts to keep pace. Source: Yahoo Finance
New weight-loss drug ETF
“Roundhill Investments' GLP-1 & Weight Loss ETF (OZEM), which began trading last week, pairs leaders Eli Lilly and Novo Nordisk with players developing new treatments for weight loss and diabetes. CEO Dave Mazza said his firm is capitalizing on explosive growth potential in the industry…Eli Lilly and Novo Nordisk each hold a roughly 20% weighting in the ETF. The three next largest positions are Zealand Pharma, Amgen and Chugai Pharmaceutical, each of which have a weighting under 5%”. Source: CNBC, Bloomberg
